Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Total revenue | 1,629 | 1,777 | 3,625 | 3,232 |
| Costs and expenses: | ||||
| Cost of revenue | 218 | 515 | 613 | 1,021 |
| Research and development | 18,066 | 11,449 | 33,723 | 23,033 |
| General and administrative | 6,048 | 5,386 | 12,791 | 11,525 |
| Licensing | 1,235 | 1,335 | 2,628 | 2,345 |
| Revaluation of contingent consideration | 300 | 1,500 | 300 | 1,800 |
| Total costs and expenses | 25,867 | 20,185 | 50,055 | 39,724 |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's R&D?
- Aclaris Therapeutics (ACRS) reported R&D of $18.07M in Q2 2026.
- How has Aclaris Therapeutics's R&D changed year-over-year?
- Aclaris Therapeutics's R&D increased by 57.8% year-over-year, from $11.45M to $18.07M.
- What is the long-term trend for Aclaris Therapeutics's R&D?
- Over 4 years (2021 to 2025), Aclaris Therapeutics's R&D has grown at a 4.7% compound annual growth rate (CAGR), from $43.81M to $52.65M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Aclaris Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude